You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 7,794,711

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,794,711

Title:	Agent for treating chondroma and chondrosarcoma
Abstract:	The present invention relates to a novel agent for treating chondroma and chondrosarcoma containing a substance which inhibits binding of parathyroid hormone related peptide to its receptor for improving the prognosis of chondroma or chondrosarcoma.
Inventor(s):	Yoshikawa; Hideki (Osaka, JP), Miyaji; Takahiro (Osaka, JP)
Assignee:	Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP)
Application Number:	10/533,584
Patent Claims:	1. A method for treating chondroma and chondrosarcoma, which comprises administering, to a subject in need thereof, a substance which inhibits binding of parathyroid hormone related peptide to a receptor thereof, wherein the substance is humanized anti-PTHrP(1-34) antibody wherein the L chain V domain comprises a polypeptide with any one of the amino acid sequences of SEQ ID NOs: 48-55 and the H chain V domain comprises a polypeptide with the amino acid sequence of SEQ ID NO: 56. 2. A method of inducing apoptosis in chondroma and chondrosarcoma cells by administering a substance which inhibits binding of parathyroid hormone related peptide and a receptor thereof, wherein the substance is humanized anti-PTHrP(1-34) antibody wherein the L chain V domain comprises a polypeptide with any one of the amino acid sequences of SEQ ID NOs: 48-55 and the H chain V domain comprises a polypeptide with the amino acid sequence of SEQ ID NO: 56. 3. The method according to claim 2, wherein the apoptosis is induced through the control of Bcl-2/Bax by the humanized anti-PTHrP(1-34) antibody wherein the L chain V domain comprises a polypeptide with any one of the amino acid sequences of SEQ ID NOs: 48-55 and the H chain V domain comprises a polypeptide with the amino acid sequence of SEQ ID NO: 56. 4. The method according to claim 2, wherein the apoptosis is induced through the control of caspase 3 by humanized the anti-PTHrP(1-34) antibody wherein the L chain V domain comprises a polypeptide with any one of the amino acid sequences of SEQ ID NOs: 48-55 and the H chain V domain comprises a polypeptide with the amino acid sequence of SEQ ID NO: 56. 5. The method according to claim 2, wherein the apoptosis is induced in vivo. 6. The method according to claim 2, wherein the apoptosis is induced in vitro.

Details for Patent 7,794,711

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015	⤷ Try a Trial	2022-11-18
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.